ORIGINAL ARTICLE

Chronic prescription of antidepressant medication in patients with chronic kidney disease with and without kidney replacement therapy compared with matched controls in the Dutch general population

Manon J.M. van Oosten1,∗, Dan Koning2,∗, Susan J.J. Logtenberg2, Martijn J.H. Leegte3, Henk J.G. Bilo4,5, Marc H. Hemmelder6, Kitty J. Jager1 and Vianda S. Stel1

1Department of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands, 2Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands, 3Dutch Renal Registry, Nefrovisie Foundation, Utrecht, The Netherlands, 4Department of Internal Medicine, University Medical Center, Groningen, and Faculty of Medicine, Groningen University, Groningen, The Netherlands, 5Diabetes Research Center and Department of Epidemiology and Statistics, Isala Hospital, Zwolle, The Netherlands and 6Department of Internal Medicine, Division of Nephrology, Maastricht Universal Medical Center and Cardiovascular Research Institute University Maastricht, Maastricht, The Netherlands

∗These authors contributed equally to this work.
Correspondence to: Manon J.M. van Oosten; E-mail: m.j.m.vanoosten@amsterdamumc.nl

ABSTRACT

Background. Chronic kidney disease (CKD) is associated with a higher prevalence of depression, neuropathic pain and insomnia. These conditions are often treated pharmaceutically. In this study we aimed to determine the prevalence of chronic antidepressant use among CKD patients with and without kidney replacement therapy (KRT).

Methods. By using the Dutch health claims database, we were able to determine the prevalence, type and dosage of chronic antidepressant prescriptions in patients with CKD Stage G4/G5 without KRT (n = 14 905), patients on dialysis (n = 3872) and patients living on a functioning graft (n = 8796) and compared these to age-, sex- and socio-economic status (SES)-matched controls from the general population.

Results. Our data show that the prevalence of chronic antidepressant prescription is 5.6%, 5.3% and 4.2% in CKD Stage G4/G5, dialysis and kidney transplant patients, respectively, which is significantly higher than in matched controls. Although our data revealed more prescriptions in female patients and in the age category 45–64 years, our data did not show any association between antidepressant prescriptions and SES. Selective serotonin reuptake inhibitors were the most prescribed drugs in all patient groups and controls. Tricyclic antidepressants were more often used in patients compared with controls.

Received: 20.9.2021; Editorial decision: 24.11.2021

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Conclusion. This nationwide analysis revealed that chronic antidepressant prescription in the Netherlands is higher in CKD patients with and without KRT than in controls, higher in middle-aged patients and women, unrelated to socio-economic status and lower than chronic use reported in other countries.

GRAPHICAL ABSTRACT

CKD is associated with higher prevalence of depression, neuropathic pain, and insomnia. The aim of the study was to determine the prevalence of chronic antidepressant use among CKD patients with and without KRT.

Methods
Dutch health claims data
Chronic antidepressant prescription:
• Prevalence
• Type
• Dosage
CKD G4/G5: 14,905 patients
Dialysis: 3,872 patients
Transplantation: 8,796 patients
Controls are matched for age, sex, socioeconomic status

Results
Antidepressant prescription
Patients Controls
Significantly higher prescription among patients (compared with controls)

5.6% 2.8%
5.3% 3.0%
4.2% 2.7%

Especially among:
• female patients
• 45–64 years category

SSRI: most prescribed antidepressant drug in both patients and controls
Tricyclic antidepressants: more often prescribed to patients than to controls

INTRODUCTION

Chronic kidney disease (CKD) is associated with substantial co-morbidity. In addition to well-known cardiovascular pathology, CKD is associated with a number of neuropsychiatric conditions, including neuropathic pain, sleeping disorders, depressive mood disorder and anxiety [1–3]. Various non-pharmaceutical therapies are available for these conditions, such as lifestyle modification or cognitive behavioural therapy. If these prove ineffective or when disease burden is high, pharmaceutical intervention by prescribing antidepressant medication can be considered. The results of several studies suggest that in CKD, the use of antidepressants is associated with higher mortality [4, 5], although this is not consistently demonstrated [6].

Current literature suggests that antidepressant use in CKD with and without kidney replacement therapy (KRT) varies between 5.2% and 29.1% [4, 6–8]. In CKD patients without KRT, antidepressant use appears to be substantially higher than in age- and sex-matched controls without CKD [8]. However, in studies on antidepressant use in dialysis-dependent and kidney transplant patients, a control group has been lacking. Moreover, previous studies were restricted to samples and did not use comprehensive, nationwide data [9, 10]. Our study aims to examine chronic antidepressant use in patients with CKD stage G4/G5 without KRT, patients on dialysis treatment and patients with a functioning kidney transplant compared with matched controls from the general population. To this end we analysed data derived from a national health insurance database that covers the entire Dutch CKD population.

MATERIALS AND METHODS

Vektis database
For this study we used Dutch health claims data from the Vektis database. Since health insurance is mandatory in the Netherlands, ~99% of Dutch residents are insured, of whom 99% are included in the database. This database contains all reimbursement data for healthcare products covered by the Dutch Health Insurance Act, as well as demographic data such as an individual's year of birth, sex, postal code, socio-economic status (SES) and date of death (if applicable) [11]. The SES of each individual is based on a person’s postal code and is a reflection of the average income, education level and position in the labour market in that area of residence [12]. The mean SES score in the Netherlands has been set at 0 and ranges from –6.75 to +3.06, where a lower score indicates a lower SES and a higher score indicates a higher SES [12].

Keywords: antidepressant medication, chronic kidney disease, depression, dialysis, kidney transplantation

van Oosten M.J.M., Koning D. et al.
Clinical Kidney Journal (2021)
m.j.m.vanoosten@amsterdamumc.nl
@CKJsocial
In the Netherlands, all hospital procedures are reimbursed via physician claims called Diagnosis Treatment Combinations (DBC) [13]. Every DBC corresponds to a given medical diagnosis in a given medical discipline. Furthermore, Vektis contains pharmacy dispensing data with information regarding the World Health Organization’s (WHO’s) Anatomical Therapeutic Chemical (ATC) classification system, the daily defined dose (DDD) and the annual quantity of a supplied medication [14]. The DDD reflects the assumed average maintenance dose per day for a medication used for its main indication. The annual quantity of a specific medication is a product of the DDD and the number of days a medication was dispensed. For example, an annual DDD of 180 may indicate the use of a medication in its routine dose during 180 days or half of the routine dose during 360 days. Vektis has no information on medication administered in intramural settings, such as during a hospital admission, a dialysis treatment or a nursing home stay. Furthermore, Vektis does not include data on over-the-counter drugs.

Since the Vektis database lacks detailed clinical information, we used proxies to assess the prevalence of chronic conditions in our study population. The variables diabetes mellitus, macrovascular disease (including coronary artery disease, peripheral artery disease and cerebrovascular accident (CVA)/transient ischemic attack (TIA)), and malignancies were based on combinations of DBC codes, primary care codes and medication use [15]. The variables chronic obstructive pulmonary disease (COPD) and Parkinson’s were based on medication profiles, i.e. Pharmaceutical Cost Groups, which have been shown to provide reliable estimates of chronic disease burden [16–19]. The variables hospitalization and intensive care unit (ICU) admission were based on operational codes, an element of the DBC code. See Supplementary data, Section S1 for the variable definitions.

Study population

We identified adults (i.e. ≥20 years of age) with CKD Stage G4/G5 (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²) without KRT, patients on dialysis treatment (regardless of dialysis modality) and patients with a functioning kidney transplant. Patients were identified and allocated to the patient groups by a DBC for CKD Stage G4/G5, dialysis or kidney transplantation on 1 January 2017 [20]. Patients with CKD Stage G4/G5 without KRT who started KRT in 2017 and patients switching KRT modality in 2017 (from dialysis to kidney transplantation or vice versa) were excluded from the study (n = 7229). Furthermore, individuals were excluded in case of incomplete data, if they died during the study year or if we were unable to match them to controls.

A control group was created for each patient group separately by randomly selecting two controls per patient out of all individuals in the Vektis database provided that they had no CKD-related healthcare claim in 2017. Controls were matched for age, sex and SES score.

Antidepressant prescription

Antidepressant prescription was defined by drugs listed in the WHO’s ATC classification system, code N06A Antidepressants (see Supplementary data, Section S2 for drugs listed to code N06A) [14]. We selected antidepressants with a cumulative annual DDD ≥ 180 to define chronic antidepressant use as our main outcome. In addition, total antidepressant prescription was defined as a DDD ≥ 0.

Statistical analyses

Baseline characteristics were described using medians and percentiles for continuous variables that were not normally distributed and frequency distributions with percentages for categorical variables. For the variable age, which was not normally distributed, we also presented the mean and standard deviation (SD). We calculated antidepressant prescription in all patient (sub)groups and controls and expressed it as a percentage. Baseline characteristics and antidepressant prescription in subgroups were compared using a Student’s t-test for normally distributed continuous variables, Mann–Whitney U-test for not normally distributed continuous variables and chi-squared test for categorical variables. We considered P-values < 0.05 as statistically significant. Analyses were performed in SAS, version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS

Patient characteristics

In total, 14 905 CKD G4/G5, 3872 dialysis and 8796 transplant patients were included. Baseline characteristics are shown in Table 1. The mean age ranged from 56.5 years in transplant patients to 75.6 years in CKD G4/G5 patients, whereas the percentage of males ranged from 52.8% in the CKD G4/G5 patients to 59.8% in transplant patients. The median SES ranged from −0.1 (kidney transplantation) to −0.4 (dialysis). The percentage of patients suffering from diabetes mellitus, macrovascular disease and COPD was significantly higher in patients compared with controls (P < 0.001). Furthermore, the percentage of patients with malignancy, hospitalization or ICU admission was higher in all patients compared with controls (P < 0.001).

Chronic antidepressant prescription

Figure 1 shows the percentage of chronic antidepressant prescription in patients and controls. Overall, antidepressant prescription was higher in patients than in controls; i.e. CKD G4/G5 patients (5.6% versus 2.8%; P < 0.001), dialysis patients (5.3% versus 3.0%; P < 0.001) and transplant patients (4.1% versus 2.7%; P < 0.001). In both patients and controls, antidepressant prescription was highest between 45 and 64 years of age and lowest in patients and controls ages 20–44 years, with the exception of CKD G4/G5 patients, where prescription was lowest in patients ≥ 75 years of age. In both patients and controls, women were prescribed antidepressants more often than men (Figure 1). Frequencies ranged from 5.5% to 7.9% in female patients and from 3.3% to 4.1% in males, while in controls this was 3.7–4.3% in women and 2.0%–2.1% in men (Figure 1). Variation in prescriptions between the different SES groups was small.

In Supplementary data, Figure S1 and Table S3, we present the percentage of total antidepressant prescriptions (DDD > 0) in patients and controls. Similar patterns were observed as in chronic antidepressant prescription, albeit at higher prescription frequencies. Total antidepressant prescriptions were higher in patients than in controls (CKD G4/G5: 10.6% versus 5.6% (P < 0.001); dialysis: 12.1% versus 5.4% (P < 0.001); transplantation 7.8% versus 4.4% (P < 0.001)).

Type of antidepressants

Among patients who were prescribed antidepressant medication, selective serotonin reuptake inhibitors (SSRIs) were the most prevalent type of antidepressant medication, ranging from
### Table 1. Baseline characteristics of CKD Stage G4/G5 without KRT, dialysis and kidney transplant patients and matched controls

| Characteristics                                    | CKD Patients (n = 14,905) | Matched controls (n = 29,810) | P-value | CKD Patients (n = 3,872) | Matched controls (n = 7,744) | P-value | CKD Patients (n = 8,796) | Matched controls (n = 17,592) | P-value |
|----------------------------------------------------|---------------------------|-------------------------------|---------|---------------------------|-------------------------------|---------|---------------------------|-------------------------------|---------|
| Age (years), mean (SD)                             | 75.6 (11.2)               | 75.6 (11.2)                  | 1.00    | 70.8 (13.2)               | 70.8 (13.2)                  | 1.00    | 56.5 (13.6)               | 56.5 (13.6)                  | 1.00    |
| Age (years), median (25th–75th percentile)         | 78.0 (70.0–84.0)          | 78.0 (70.0–84.0)             | 1.00    | 74.0 (64.0–80.0)          | 74.0 (64.0–80.0)             | 1.00    | 58.0 (48.0–67.0)          | 58.0 (48.0–67.0)             | 1.00    |
| 20–44 (%)                                          | 1.8                       | 1.8                          | 1.00    | 4.5                       | 4.5                          | 1.00    | 19.6                      | 19.6                         | 1.00    |
| 45–64 (%)                                          | 12.2                      | 12.2                         | 1.00    | 22.5                      | 22.5                         | 1.00    | 48.4                      | 48.4                         | 1.00    |
| 65–74 (%)                                          | 25.0                      | 25.0                         | 1.00    | 47.3                      | 47.3                         | 1.00    | 24.5                      | 24.5                         | 1.00    |
| ≥75 (%)                                            | 61.0                      | 61.0                         | 1.00    | 58.8                      | 58.8                         | 1.00    | 7.5                       | 7.5                          | 1.00    |
| Sex (male), %                                      | 52.8                      | 52.8                         | 1.00    | 58.8                      | 58.8                         | 1.00    | 59.8                      | 59.8                         | 1.00    |
| SES, Median (quartile 1–quartile 3)                | –0.2 (−1.0–0.5)           | –0.2 (−1.0–0.5)              | 1.00    | –0.4 (−1.2–0.3)           | –0.3 (−1.2–0.4)              | 1.00    | –0.1 (−1.0–0.6)           | –0.1 (−1.0–0.6)              | 1.00    |
| Quartile 1 (%)                                      | 28.1                      | 28.1                         | 1.00    | 33.6                      | 33.6                         | 1.00    | 27.6                      | 27.6                         | 1.00    |
| Quartile 2 (%)                                      | 26.5                      | 26.5                         | 1.00    | 26.6                      | 26.6                         | 1.00    | 24.9                      | 24.9                         | 1.00    |
| Quartile 3 (%)                                      | 25.2                      | 25.2                         | 1.00    | 22.4                      | 22.4                         | 1.00    | 23.7                      | 23.7                         | 1.00    |
| Quartile 4 (%)                                      | 20.2                      | 20.2                         | 1.00    | 17.4                      | 17.4                         | 1.00    | 23.9                      | 23.9                         | 1.00    |
| Diabetes mellitus (%)                              | 32.3                      | 8.9                          | <0.001  | 29.6                      | 8.8                          | <0.001  | 27.8                      | 4.4                          | <0.001  |
| Macrovascular disease (%)                          | 17.7                      | 5.4                          | <0.001  | 29.2                      | 4.8                          | <0.001  | 11.3                      | 2.4                          | <0.001  |
| Coronary artery disease (%)                        | 8.7                       | 4.6                          | <0.001  | 13.2                      | 4.5                          | <0.001  | 5.9                       | 2.3                          | <0.001  |
| Peripheral artery disease (%)                      | 8.4                       | 1.9                          | <0.001  | 16.9                      | 1.8                          | <0.001  | 4.9                       | 0.7                          | <0.001  |
| COPD (%)                                           | 2.5                       | 1.7                          | <0.001  | 3.6                       | 1.4                          | <0.001  | 1.6                       | 0.8                          | <0.001  |
| Parkinson’s (%)                                     | 7.1                       | 3.1                          | <0.001  | 5.6                       | 2.7                          | <0.001  | 2.1                       | 1.2                          | <0.001  |
| Malignancies (%)                                    | 0.6                       | 0.6                          | 0.832   | 0.6                       | 0.5                          | 0.789   | 0.4                       | 0.2                          | 0.001   |
| Hospitalization (%)                                | 28.7                      | 8.7                          | <0.001  | 52.3                      | 7.6                          | <0.001  | 28.8                      | 4.3                          | <0.001  |
| ICU admittance (%)                                  | 2.6                       | 0.7                          | <0.001  | 8.4                       | 0.5                          | <0.001  | 2.5                       | 0.4                          | <0.001  |
55.1% in CKD G4/G5 to 65.1% in transplant patients (Table 2). SSRI prescription was consistently lower in patients compared with controls, although this difference was only statistically significant in the CKD group (55.1% versus 62.0%; P = 0.004). The frequency of tricyclic antidepressant (TCA) prescription was 23.4%, 23.0% and 18.7% in CKD G4/G5, dialysis and transplant patients, respectively, and was significantly higher in all patient groups compared with controls. Citalopram and paroxetine were the most often prescribed SSRIs (Table 2). Regarding TCAs, amitriptyline was significantly more often prescribed in all three patient groups compared with their control groups (P < 0.01). In transplant patients, nortriptyline was more often prescribed than in controls (P = 0.034). Mirtazapine (tetracyclic antidepressant) and venlafaxine (selective noradrenalin reuptake inhibitor) were the most commonly prescribed ‘other’ types of antidepressants.

**DISCUSSION**

We conducted the first nationwide study assessing chronic antidepressant prescription in patients with CKD Stage G4/G5 with and without KRT compared with age-, sex- and SES-matched controls. In this study, the percentage of prescribed antidepressants was higher in CKD patients than in the matched general population without CKD. Around 6% of CKD Stage G4/G5 patients, 5% of dialysis patients and 4% of transplant patients were chronically prescribed antidepressants compared with ~3% in the control groups. Antidepressant prescription was highest in patients ages 45–64 years. In both patients and controls, women were more likely to be prescribed antidepressant medication. Furthermore, antidepressant prescribing in CKD patients was comparable across SES categories, which suggests that there is...
Table 2. Prescription rates of the different classes of antidepressants and individual antidepressants in CKD Stage G4/G5, dialysis and kidney transplantation patients and matched controls using antidepressants

| Antidepressants | CKD | Dialysis | Kidney transplantation |
|-----------------|-----|----------|-----------------------|
|                 | Patients | Controls | P-value | Patients | Controls | P-value | Patients | Controls | P-value |
| SSRI (%)        | 55.1 | 62.0     | 0.004    | 61.3 | 67.1     | 0.206    | 65.1 | 69.7     | 0.156     |
| Citalopram      | 19.6 | 21.5     | 0.334    | 26.0 | 19.0     | 0.083    | 21.7 | 21.0     | 0.792     |
| Paroxetine      | 19.0 | 22.8     | 0.056    | 20.6 | 28.1     | 0.068    | 20.6 | 25.1     | 0.125     |
| Sertraline      | 6.5  | 5.9      | 0.640    | 4.4  | 8.7      | 0.076    | 10.7 | 8.9      | 0.383     |
| Escitalopram    | 4.1  | 5.8      | 0.103    | 4.9  | 4.8      | 0.946    | 5.8  | 6.6      | 0.605     |
| Other b         | 6.6  | 7.5      | n.d.     | 5.9  | 7.4      | n.d.     | 7.4  | 9.8      | n.d.      |
| TCA (%)         | 23.4 | 19.5     | 0.048    | 23.0 | 14.7     | 0.026    | 18.7 | 11.0     | 0.002     |
| Amitriptyline   | 13.1 | 8.3      | 0.002    | 17.7 | 7.8      | 0.002    | 11.3 | 4.8      | <0.001    |
| Nortriptyline   | 7.3  | 7.4      | 0.980    | 4.9  | 4.3      | 0.776    | 4.7  | 2.1      | 0.034     |
| Other a         | 3.5  | 3.9      | n.d.     | 2.0  | 3.0      | n.d.     | 3.3  | 4.2      | n.d.      |
| Other (%)       | 30.4 | 28.9     | 0.489    | 27.9 | 26.4     | 0.720    | 26.4 | 28.4     | 0.509     |
| Mirtazapine     | 16.8 | 15.8     | 0.568    | 20.6 | 14.3     | 0.083    | 12.6 | 10.8     | 0.405     |
| Venlafaxine     | 8.8  | 10.0     | 0.399    | 7.8  | 8.7      | 0.758    | 8.2  | 13.1     | 0.026     |
| Other c         | 6.1  | 5.3      | n.d.     | 3.9  | 5.6      | n.d.     | 5.6  | 6.4      | n.d.      |

n.d.: not determined.
The table shows the percentages of (type of) antidepressant prescribed in individuals with an antidepressant prescription. The prescription rates of SSRIs, TCAs and other add up to >100%, which indicates that some individuals were prescribed more than one antidepressant from different classes.

bClomipramine, imipramine, doxepine, maprotiline and dosulepine.
cBupropion, duloxetine, trazodone, agomelatine, vortioxetine and mianserine.

There is no association between education level and chronic antidepressant prescribing. SSRIs were the antidepressant of choice in patients being prescribed antidepressants; with 55% of CKD, 61% of dialysis and 65% of kidney transplant patients using a drug from this class of antidepressants. Interestingly, TCAs were prescribed significantly more often in patients compared with controls.

Strengths and limitations

In this study we used a comprehensive data source of routinely collected health claims data comprising ~98% of all Dutch inhabitants. This enabled us to study CKD Stage G4/G5 patients with and without KRT in the same study cohort and to select a matched control group from the general population. Pharmacy dispensing data, which was used to determine antidepressant prescription in this study, is generally considered the most accurate way to determine medication use in large populations as opposed to medication reviews from patient interviews or medical charts that are vulnerable to recall bias or incomplete registration [21]. Furthermore, our data allowed for the selection of chronically prescribed antidepressant medication representing a group of patients with clinically significant depressive symptoms present for a prolonged period of time. An additional advantage of pharmacy dispensing data is that they only represent prescribed medication that is truly dispensed by the pharmacy and accordingly collected by the patient. Although medication adherence remains difficult to quantify, regular medication dispensing by a pharmacy is a strong indicator that this medication was routinely used by the patient.

Several limitations of this study must also be acknowledged. First, the validity of study results must be discussed when health claims codes are being used to identify a study population. Previously we showed that Dutch health claims data from the Vektis database provide reliable estimates of the Dutch dialysis and kidney transplantation population since the correspondence between the Dutch renal registry data and the Vektis data was very high (99%) [20]. The overall sensitivity to identify patients with CKD Stage G4/G5 (eGFR <30 mL/min/1.73 m²) using Dutch health claims data was low (51%), although sensitivity was higher in younger patients. The relatively low validity can be explained by the fact that patients solely treated in primary care cannot be identified using hospital claims data. As a result, especially elderly patients and patients with limited comorbidities are underrepresented in the CKD Stage G4/G5 group [22]. Consequently there is a chance that unidentified CKD patients in our study were selected as controls.

Second, we were unable to determine the indication for the prescription of antidepressants. Besides the treatment of depressive symptoms, antidepressants can be prescribed for other diagnoses such as neuropathic pain or anxiety, which are both more common among CKD patients than in the general population [1–3].

Antidepressant use

CKD Stage G4/G5 without KRT. Antidepressant use in CKD patients without KRT has been described in previous studies originating from the USA and UK [4, 7, 8, 23, 24]. The 2020 United States Renal Data System (USRDS) report describes SSRI prescription drug coverage, based on 6-month prescriptions, in CKD Stage 4 and 5 patients being 22.4% and 21.8%, respectively (of note: this USRDS report only described patients >65 years of age and coverage of other antidepressants is not reported) [23]. Two studies by Fischer et al. [7, 24] report antidepressant use, derived from patient interviews, in CKD patients (eGFR <60 mL/min/1.73 m²) using data from two different US cohorts among patients with a mean age of ~60 years. Antidepressant use of 18.2% was reported in the Chronic Renal Insufficiency Cohort and 5.4% in the African American Study of Kidney Disease and Hypertension Cohort [7, 24]. Finally, Balogun et al. [4] reported antidepressant use of 29.1% using Medicare pharmacy dispensation data from the national Veterans Affairs Health System database, a cohort of elderly (mean age 74 years) CKD patients...
M. J. M. van Oosten

**Because of their lower risk of side effects compared with TCAs, vises SSRIs for treatment of patients with depressive disorders,**

The Dutch clinical practice guideline addiction with other studies.

**Transplant patients,** we found a lower prevalence of both chronic antidepressant prescriptions were 12.8% in the year before transplant.

Information on antidepressant use in the USRDS [5] studied antidepressant prescriptions in the year before and other two studies where antidepressant use was based on patient medication, the duration of prescriptions is not known for the other studies. Where the USRDS reports chronically prescribed medication, the duration of prescriptions is not known for the other two studies where antidepressant use was based on patient interview and chart review [23, 25, 26]. The results of these latter studies are in concordance with our reported total antidepressant prescription rate of 12.1% in dialysis patients [25, 26].

**Kidney transplantation.** Information on antidepressant use in kidney transplant patients is scarce. The 2020 USRDS report described SSRI use of 19.6% in transplant patients [23]. Lentine et al. [5] studied antidepressant prescriptions in the year before and after transplantation using US pharmacy claims data. Antidepressant prescriptions were 12.8% in the year before transplantation, of which 51.8% of the patients continued use after transplantation and 13.2% started use after transplantation. Among transplant patients, we found a lower prevalence of both chronic (4.1%) and total (7.8%) prescriptions of antidepressants in comparison with other studies.

**Prescribing patterns.** The Dutch clinical practice guideline advises SSRIs for treatment of patients with depressive disorders, because of their lower risk of side effects compared with TCAs, and prefers the prescription of SSRIs citalopram and sertraline and the TCA nortriptyline in older individuals [27]. In line with this guideline, the results of our study show that most older patients were prescribed citalopram. However, the results of our study do not show a preference for nortriptyline over amitriptyline in older individuals. This may change in the coming years as prescribers may gradually become aware of the beneficial effects of nortriptyline [28]. Our data are broadly consistent with previously conducted studies in CKD patients describing the preference of SSRIs over TCAs [5, 7, 8, 25]. Data on the specific type of antidepressant are scarce, but two studies by Iwagami et al. [8] and Guirguis et al. [25] report that citalopram is the most commonly prescribed antidepressant in CKD and dialysis patients.

**Prescription of antidepressants in the general population.** The antidepressant prescription of ~3% in our matched control groups is lower compared with data from the general population in the Netherlands showing that ~6% of all Dutch inhabitants were prescribed antidepressants in 2019 [29]. This difference might be explained by the older age of the matched control groups, as our results suggest that antidepressant use decreases with age. Antidepressant use in adults seems to be higher in the USA (13.2%) compared with Europe (7.2%) [9]. Of note, the percentage of antidepressant use in Europe varies widely per country, from 15.7% in Portugal to 2.7% in Greece [9].

**Factors related to antidepressant prescription.** Variations in antidepressant prescription between countries are the result of a complex interplay of factors such as the prevalence of depression, certain stigmata about depression, a country’s healthcare spending and coverage and the availability of other treatment options for depression [9, 10]. The high percentage of antidepressant prescriptions in CKD patients in the USA is in line with the known high antidepressant rates in the US population, which is among the highest in the world [10]. On the other hand, a recent study by Hayward et al. [30] demonstrated that the chance of hyperpolypharmacy in older patients with advanced CKD was twice as high in the Netherlands as in the UK. In light of this study, it is perhaps remarkable that this does not hold true for antidepressants—the prescription of antidepressants in CKD patients with and without KRT seems to be lower in the Netherlands than in the UK. The results of the study by Hayward et al. [30] imply a generally reserved prescribing approach of UK physicians towards patients with CKD, whereas the results of our study suggest a restrictive prescribing approach, particularly antidepressants, in the Netherlands.

**CONCLUSION**

This nationwide analysis of Dutch pharmacy dispensing data shows that chronic antidepressant prescription was significantly higher in CKD patients with and without KRT compared with their matched controls from the general population. Prescription was lower in elderly patients and in men, yet unrelated to SES. This study reveals an importantly lower prescription rate of antidepressants in Dutch CKD patients than that reported in CKD patient populations elsewhere. It is difficult to assess to what extent the intercountry variation is a result of under- or overprescription.

**SUPPLEMENTARY DATA**

Supplementary data are available at ckj online.
CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Cukor D, Coplan J, Brown C et al. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol 2007; 2: 484–490
2. Shirazian S, Grant CD, Aina O et al. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep 2017; 2: 94–107
3. Kumar P, Clark M. Kidney and urinary tract diseases. In: Feather A, Randall D, Waterhouse M (eds). Clinical Medicine. Amsterdam: Elsevier, 2012: 618–621
4. Balogun RA, Abdel-Rahman EM, Balogun SA et al. Association of depression and antidepressant use with mortality in a large cohort of patients with nondialysis-dependent CKD. Clin J Am Soc Nephrol 2012; 7: 1793–1800
5. Lentine KL, Naik AS, Ouseph R et al. Antidepressant medication use before and after kidney transplant: implications for outcomes—a retrospective study. Transpl Int 2018; 31: 20–31
6. Tuot DS, Lin F, Norris K et al. Depressive symptoms associate with race and all-cause mortality in patients with CKD. Kidney Int Rep 2019; 4: 222–230
7. Fischer MJ, Xie D, Jordan N et al. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC studies. Am J Kidney Dis 2012; 60: 27–38
8. Iwagami M, Tomlinson LA, Mansfield KE et al. Prevalence, incidence, indication, and choice of antidepressants in patients with and without chronic kidney disease: a matched cohort study in UK clinical practice research data-link. Pharmacoepidemiol Drug Saf 2017; 26: 792–801
9. Lewer D, O’Reilly C, Mojtabai R et al. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br J Psychiatry 2015; 207: 221–226
10. Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015–2018. NCHS Data Brief 2020; 377: 1–8
11. de Boor A. Vektis: information centre for healthcare. Tijdschr Gezondheidszaken 2011; 89: 358–359
12. Knol F. Statusontwikkeling van wijken in Nederland 1998–2010. Den Haag: Sociaal en Cultureel Planbureau, 2012
13. Westerdijk M, Zuurbier J, Ludwig M et al. Defining care products to finance health care in the Netherlands. Eur J Health Econ 2012; 13: 203–221
14. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2020. 23rd ed. Oslo: 2019. http://www.whocc.no/filearchive/publications/2020_guidelines_web.pdf (August 2021, date last accessed)
15. van Oosten MJM, Logtenberg SJ, Hemmelder MH et al. Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls. Clin Kidney J. 2021; 14: 2497–2523
16. Chini F, Pezzotti P, Orzella L et al. Can we use the pharmacy data to estimate the prevalence of chronic conditions? A comparison of multiple data sources. BMC Public Health 2011; 11: 688.
17. Lamers LM. Pharmacy costs groups: a risk-adjuster for capitation payments based on the use of prescribed drugs. Med Care 1999; 37: 824–830
18. Slobbe LCJ, Füssennich K, Wong A et al. Estimating disease prevalence from drug utilization data using the Random Forest algorithm. Eur J Public Health 2019; 29: 615–621
19. Tamblyn R, Lavoie G, Petrella L et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in québec. J Clin Epidemiol 1995; 48: 999–1009
20. Mohnen SM, van Oosten MJM, Los J et al. Healthcare costs of patients on different renal replacement modalities—analysis of Dutch health insurance claims data. PLoS One 2019; 14: e0220800
21. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: P323–337
22. van Oosten MJM, Logtenberg SJ, Leegte MJH et al. Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data. Nephrol Dial Transplant 2020; 35: 2138–2146
23. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2020
24. Fischer MJ, Kimmel PL, Greene T et al. Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease. Kidney Int 2010; 77: 1010–1019
25. Guirguis A, Chilcot J, Almond M et al. Antidepressant usage in haemodialysis patients: evidence of sub-optimal practice patterns. J Renal Care 2020; 46: 124–132
26. Lopes AA, Albert JM, Young EW et al. Screening for depression in haemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004; 66: 2474–2475
27. Nederlands Huisartsen Genootschap. NHG Richtlijn Depressie. 2019. https://richtlijnen.nhg.org/standaarden/depressie (31 December 2021, date last accessed)
28. Stichting Farmaceutische Kengetallen. Apotheken scoren beter op nortriptyline-indicator. https://www.sfk.nl/publicaties/PW/2019/apotheken-scoren-beter-op-nortriptyline-indicator (31 December 2021, date last accessed)
29. Central Bureau of Statistics. Persons with dispensed medicines. 2019. http://opendata.cbs.nl/#/CBS/en/ (August 2021, date last accessed)
30. Hayward S, Hole B, Denholm R et al. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European quality study. Nephrol Dial Transplant 2021; 36: 503–511